InvestWiser

Vivesto AB

VIVENasdaq StockholmHealthcareMarket value 79 m SEK
7.14SEK −1.2%
last day · Price as of 18 November 2026

The answer first

Does Vivesto beat the market?

No, Vivesto has not beaten the market over the last year.

Vivesto−64.8%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 32% of Nordic stocks

    • Quality61
    • Value58
    • Trend7

    No. 98 of 195 in healthcare

Max for seven days

Follow Vivesto with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Vivesto

From today, at a price of 7.14 SEK. Write why you follow Vivesto, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Vivesto

Your first answer is free, no account needed.

Do you own Vivesto, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Vivesto and a few more. Free, no card.

Past year against the exchange and Super Stock
Vivesto−64.8%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Vivesto has fallen 64.8% over the past year, including dividends.
  • Overall, Vivesto ranks better than 32% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 96.2%. The price is 99.6% below its peak now.

What do analysts think of Vivesto?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

32

Quality, value and trend together. Better than 32% of Nordic stocks.

No. 98 of 195 in healthcare

Quality61
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 105 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.13
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−20.1%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value58
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 33 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.5
  • P/SPrice divided by salesnegative earnings
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend7
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 164 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−19.0%
  • 6 months−50.4%
  • 9 months−14.3%
  • 12 months−64.8%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+2.1%
3 years, per year
−26.7%
5 years, per year
−47.7%
10 years, per year
−35.4%
Largest fall, 3 years
−96.2%
From a peak to the bottom
From the peak now
−99.6%
How far the price is from the peak
Volatility, 1 year
62.4%
How much the price swings over a year
Beta, 1 year
0.26
How much the price moves when the market moves

Return with dividends reinvested.

About Vivesto

Vivesto AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.

Vivesto AB (publ) develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma. The company also provides Apealea, an injectable formulation of paclitaxel for the treatment of various cancers. In addition, it develops Cantrixil, a drug candidate for the treatment of advanced cancer, and Docetaxel micellar for the treatment of prostate cancer. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB (publ) in March 2022.

See the full analysis of Vivesto.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market